Skip to main content
Top
Published in: Investigational New Drugs 1/2002

01-02-2002

Phase I Clinical Trial of 5-Fluoro-Pyrimidinone (5FP), an Oral Prodrug of 5-Fluorouracil (5FU)

Authors: Patricia M. LoRusso, Sucharu Prakash, Antoinette Wozniak, Lawrence Flaherty, Mark Zalupski, Anthony Shields, Howard Sands, Ralph Parchment, Bhaskara Jasti

Published in: Investigational New Drugs | Issue 1/2002

Login to get access
Metadata
Title
Phase I Clinical Trial of 5-Fluoro-Pyrimidinone (5FP), an Oral Prodrug of 5-Fluorouracil (5FU)
Authors
Patricia M. LoRusso
Sucharu Prakash
Antoinette Wozniak
Lawrence Flaherty
Mark Zalupski
Anthony Shields
Howard Sands
Ralph Parchment
Bhaskara Jasti
Publication date
01-02-2002
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 1/2002
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1014430216434

Other articles of this Issue 1/2002

Investigational New Drugs 1/2002 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine